IDH2 and central nervous system cancer: While, there is no difference in OS in G2, G4, oligodendroglioma, oligoastrocytoma, glioblastoma, IDH-mutant, and 1p/19q co-codel in the subgroups of patients with glioma (p > 0.05) (Fig. S4).